New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
11:56 EDTFLMLFDA change on neostigmines could be significant for Flamel, says Summer Street
Summer Street notes that the FDA has changed its drug shortage website and now lists Flamel Technologies' Bloxiverz as the "first and only" approved neostigmine, which the firm thinks may mean that the FDA could be taking action to remove unapproved neostigmines from Fresenius or West-Ward Pharma. Summer Street thinks this change could be a "hugely significant" milestone for Flamel and its Eclat strategy and reiterates its Buy rating and $24.75 price target on the share.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:31 EDTFLMLOn The Fly: Closing Wrap
Subscribe for More Information
08:17 EDTFLMLFlamel Technologies announces positive results of second Micropump trial
Subscribe for More Information
December 16, 2014
08:47 EDTFLMLFlamel Technologies pullback a buying opportunity, says Summer Street
Subscribe for More Information
08:33 EDTFLMLFlamel Technologies transfers intangible property to Irish-based subsidiary
Flamel Technologies announced that it is moving all intangible property from its French entity to its Irish-based entity as a part of a global reorganization. The intangible property includes patents on its drug delivery platform technologies, clinical data sets and other intangible assets related to its pipeline of proprietary products in development. Flamel's proprietary drug delivery platforms include its Micropump and Medusa platforms. The company anticipates the transfer will result in a one-time tax payment of approximately $14M to the French government. The transfer of these assets is effectively immediately.
December 10, 2014
10:27 EDTFLMLFlamel Technologies management to meet with Roth Capital
Subscribe for More Information
December 8, 2014
07:45 EDTFLMLFlamel Technologies price target raised to $29 from $21 at SunTrust
SunTrust increased its price target on Flamel after meeting with the company's CEO, as the firm now expects the company to raise the price of its Bloxiverz drug next year beyond the firm's previous outlook. SunTrust keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use